(Q34838655)

English

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels (English)

1 reference

Europe PubMed Central

4 August 2017

1 reference

based on heuristic

inferred from title

object named as

A Prat

1

0 references

9

object named as

J Baselga

1 reference

Europe PubMed Central

4 August 2017

author name string

M Parera

2

1 reference

Europe PubMed Central

4 August 2017

B Adamo

3

1 reference

Europe PubMed Central

4 August 2017

S Peralta

4

1 reference

Europe PubMed Central

4 August 2017

M A Perez-Benavente

5

1 reference

Europe PubMed Central

4 August 2017

A Garcia

6

1 reference

Europe PubMed Central

4 August 2017

A Gil-Moreno

7

1 reference

Europe PubMed Central

4 August 2017

J M Martinez-Palones

8

1 reference

Europe PubMed Central

4 August 2017

J M del Campo

10

1 reference

Europe PubMed Central

4 August 2017

publication date

26 September 2008

1 reference

Europe PubMed Central

4 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

4 August 2017

20

1 reference

Europe PubMed Central

4 August 2017

2

1 reference

Europe PubMed Central

4 August 2017

294-297

1 reference

Europe PubMed Central

4 August 2017

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN601

21 January 2018

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN601

21 January 2018

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN601

21 January 2018

An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN601

21 January 2018

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN601

21 January 2018

Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN601

21 January 2018

Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN601

21 January 2018

Identifiers

10.1093/ANNONC/MDN601

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34838655&oldid=1984144197"